Parenteral hydralazine revisited

Journal of Emergency Medicine

Volumn 16, Issue 2, 1998, Pages 191-196

  Powers, David R ^a,c   Papadakos, Peter J ^b   Wallin, J David ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accelerated hypertension; Hydralazine; Parenteral therapy; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIAZOXIDE; ENALAPRIL; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; TRIMETAPHAN;

DISEASE SEVERITY; DRUG ACETYLATION; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SUBLINGUAL DRUG ADMINISTRATION;

EID: 17944401579     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(97)00287-4     Document Type: Article

References (47)

1. 1. The Fifth Report of the National Committee National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V), National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Arch Intern Med. 1993;153:154-83.
2. 2. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
3. 3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-38.
4. 4. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1995;35: 747-62.
5. 5. Gross F, Druey J, Meier R. Eine neue gruppe blutdrucksenkender substanzen von besonderem wirkunǵscharakter. Experientia. 1950; 6:19-21.
6. 6. Freis ED, Finnerty FA. Suppression of vasomotor reflexes in man following L-hydralazinophthalozine. Proc Soc Exp Biol Med. 1950;75:23-4.
7. 7. Schroeder HA. Effects on hypertension of sulfhydryl and hydrazine compounds. J Clin Invest. 1951;30:672-3.
8. 8. Page IH. Treatment of essential and malignant hypertension. J Am Med Assoc. 1951;147:1311-18.
9. 9. Reubi FC. Renal hyperemia induced in man by a new pthalazine derivative. Proc Soc Exp Biol Med. 1950;73:102-3.
10. 10. Assali NS, Suyemoto R. The place of the hydrazinophthalazine and thiophanium compounds in the management of hypertensive complications of pregnancy. Am J Obstet Gynecol. 1952;64:1021-36.
11. 11. Moyer JH. Hydralazine (Apresoline) hydrochloride. Arch Intern Med. 1953;91:419-39.
12. 12. Hughes WM, Dennis E, Moyer JH. Treatment of hypertension with oral reserpine alone and in combination with hydralazine or hexamethonium. Am J Med Sci. 1955;229:121-34.
13. 13. Zacest R, Gilmore E, Koch-Weser J. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med 1972;286:617-22.
14. 14. Pritchard FC, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for the treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol. 1984;148:951-63.
15. 15. Sibai BM, Spinnato JA, Watson DL, et al. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol 1984;64: 319-25.
16. 16. McLean AJ, Barron K, Du Souich P, et al. Interaction of hydralazine and hydrazone derivatives with contractile mechanisms in rabbit aortic smooth muscle. J Pharmacol Exp Ther. 1978;205: 418-25.
17. 17. Ebeige AB, Aloamaka CP. Mechanisms of hydralazine-induced relaxation of arterial smooth muscle. Cardiovasc Res 1985;19: 400-5.
18. 18 Jacobs M. Mechanism of action of hydralazine on vascular smooth muscle. Biochem Pharmacol. 1984;33:2915-19.
19. 19. Koch-Weser J. Hydralazine. N Engl J Med. 1976;295:320-3.
20. 20. Ludden TM, McNay JL, Shepherd AMM, Lin MS. Clinical pharmacokinetics of hydralazine. Clin Pharmacokin. 1982;7:185-205.
21. 21. Shepherd AMM, Ludden TM, McNay JL, Lin MS. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther. 1980;28:804-11.
22. 22. Reece PA, Cozamanis I, Zacest R. Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther. 1980;28:769-78.
23. 23. Ludden TM, Shepherd AMM, McNay JL, Lin MS. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther. 1980;28:736-42.
24. 24. Zacest R, Reece PA. Intravenous administration of hydralazine. Med J Aust. 1982;1:492-8.
25. 25. Shepherd AMM, McNay JL, Ludden TM, et al. Determinants of response to intravenous hydralazine in hypertension. Clin Pharmacol Ther. 1981;30:773-8.
26. 14C in man and dog. Drug Metab Dispos. 1974;2: 351-60.
27. 27. Reece PA, Staffordl, Prager RH, et al. Synthesis, formulation and clinical pharmacological evaluation of hydrlazine pyruvic acid hydrazone in two healthy volunteers. J Pharm Sci. 1985;74:193-6.
28. 14 in arterial walls. Proc Soc Exp Biol Med. 1966; 122:576-9.
29. 29. Lopez-Jaramillo P, Narvaez M, Calle A, et al. Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol. 1996;103:33-8.
30. 30. Koch-Weber J. Hypertensive emergencies. N Engl J Med. 1974; 290:211-14.
31. 31. Barry DI. Cerebrovascular aspects of antihypertensive treatment. Am J Cardiol. 1989;63:14C-18C.
32. 32. De Sanctis RW, Doroguazi RM, Austen WG, et al. N Engl J Med. 1987;317:1060-7.
33. 33. Rehman F, Mansoor GA, White WB. "Inappropriate" physician habits in prescribing oral nifedipine capsules in hospitalized patients. Am J Hypertens. 1996;9:1035-9.
34. 34. O'Mailia J, Sander G, Giles TD. Nifedipine induced myocardial ischemia or infarction in the treatment of hypertensive urgencies. Ann Intern Med. 1987;107:185-6.
35. 35. Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. J Am Med Assoc. 1996;275:423-4.
36. 36. Gedekoh RH, Hyashi TT, MacDonald HM. Eclampsia at Magee-Women's Hospital, 1970 to 1980. Am J Obstet Gynecol. 1981; 140:860-7.
37. 37. Dunlop JCH. Chronic hypertension and perinatal mortality. Proc R Soc Med. 1966;59:838-41.
38. 38. Burrows RF, Burrows EA. The feasability of a control population for a randomized control trial of seizure prophylaxis in the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1995;173:929-35.
39. 39. National high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990; 163:1689-712.
40. 40. Lindheimer ML, Katz AI. Hypertension in pregnancy. N Engl J Med. 1985;313:675-80.
41. 41. Wasserstrum N, Kirshon B, Rossavik I, et al. Implications of sino-aortic baroreceptor reflex dysfunction in severe preeclampsia. Obstet Gynecol. 1989;74:34-9.
42. 42. Patterson-Brown S, Robson SC, Redfern N, et al. Hydralazine boluses for the treatment of severe hypertension in pre-eclampsia. Br J Obstet Gynaecol. 1994;101:409-13.
43. 43. Harper A, Murnaghan GA. Maternal and fetal hemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynaecol. 1991;98:453-9.
44. 44. Lunell NO, Lewander R, Nyland L, et al. Acute effect of dihydralazine on uteroplacental blood flow in hypertension during pregnancy. Gynecol Obstet Invest. 1983;16:274-82.
45. 45. Spinnato JA, Sibai BM, Anderson GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J. 1986;79:559-62.
46. 46. Tietjken CS, Hurn PD, Ulatowski JA, Kirsch JR. Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Crit Care Med. 1996;24:311-22.
47. 47. Kumar S, Lal B, Misra MC. Post-mastectomy seroma: a new look into the aetiology of an old problem. J R Coll Surg Edinb. 1995; 40:292-4.